EGFR and non-small cell lung carcinoma: Osimertinib is a third-generation highly selective EGFR mutant inhibitor, which has a significant therapeutic effect in patients with non-small cell lung carcinoma (Jänne et al., 2015; Zhao et al., 2018; Rajappa et al., 2019).